Caspofungin
As of the edition of 20 October 2026, Caspofungin is a small molecule: marketed, first approved in 2001 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Cancidas
- First approved
- 26 January 2001 (US)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- Fresenius Kabi; 2 holders in all
- Registered trials
- 55, 8 stopped early
- Disease areas
- Infections; Blood and lymph; Cancer; Lungs and airways; Immune system; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 8 | 1 | 0 |
| Phase 2 | 22 | 13 | 1 | 5 |
| Phase 3 | 14 | 11 | 0 | 3 |
| Phase 4 | 8 | 5 | 1 | 0 |
| All trials | 55 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Acquired holder and Lead sponsor of trials | 2003 to now |
| Fresenius Kabi | Later holder | 2016 to now |